IRIS
PISANI, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 8.823
NA - Nord America 7.928
EU - Europa 6.093
SA - Sud America 1.066
AF - Africa 251
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 24.179
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.579
SG - Singapore 3.938
RU - Federazione Russa 2.660
VN - Vietnam 1.733
CN - Cina 1.648
IT - Italia 1.508
BR - Brasile 812
HK - Hong Kong 642
FR - Francia 357
DE - Germania 351
FI - Finlandia 221
CA - Canada 197
GB - Regno Unito 167
UA - Ucraina 157
IN - India 149
IE - Irlanda 142
NL - Olanda 133
JP - Giappone 128
AR - Argentina 106
MX - Messico 100
BD - Bangladesh 96
SE - Svezia 77
ZA - Sudafrica 67
PL - Polonia 66
IQ - Iraq 65
CI - Costa d'Avorio 62
KR - Corea 57
RO - Romania 51
EC - Ecuador 46
PH - Filippine 39
TR - Turchia 38
ID - Indonesia 33
TH - Thailandia 32
PK - Pakistan 29
AT - Austria 27
CO - Colombia 27
ES - Italia 27
TW - Taiwan 24
MK - Macedonia 23
VE - Venezuela 23
EG - Egitto 20
IR - Iran 18
KE - Kenya 18
UZ - Uzbekistan 18
BE - Belgio 17
MA - Marocco 15
NP - Nepal 15
TN - Tunisia 14
JO - Giordania 13
LT - Lituania 13
IL - Israele 12
RS - Serbia 12
UY - Uruguay 12
BG - Bulgaria 11
JM - Giamaica 11
CH - Svizzera 10
CL - Cile 10
DZ - Algeria 10
MY - Malesia 10
PE - Perù 10
PY - Paraguay 10
KZ - Kazakistan 9
SA - Arabia Saudita 9
ET - Etiopia 8
KG - Kirghizistan 8
BO - Bolivia 7
GR - Grecia 7
AE - Emirati Arabi Uniti 6
AU - Australia 6
KH - Cambogia 6
PT - Portogallo 6
BB - Barbados 5
CZ - Repubblica Ceca 5
HN - Honduras 5
MN - Mongolia 5
SI - Slovenia 5
TT - Trinidad e Tobago 5
AO - Angola 4
AZ - Azerbaigian 4
BH - Bahrain 4
BJ - Benin 4
CY - Cipro 4
DO - Repubblica Dominicana 4
EE - Estonia 4
EU - Europa 4
GE - Georgia 4
HR - Croazia 4
LV - Lettonia 4
NG - Nigeria 4
NI - Nicaragua 4
NO - Norvegia 4
OM - Oman 4
PS - Palestinian Territory 4
QA - Qatar 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
SY - Repubblica araba siriana 4
AL - Albania 3
BY - Bielorussia 3
CR - Costa Rica 3
Totale 24.107
Salva come PNG Salva come JPEG
Città #
Singapore 1.763
San Jose 1.272
Moscow 667
Ashburn 616
Hong Kong 606
Chandler 554
Beijing 504
Ho Chi Minh City 430
Hanoi 355
Santa Clara 327
Napoli 236
Hefei 231
Los Angeles 231
Millbury 217
Lauterbourg 208
Naples 187
The Dalles 175
Princeton 157
Nanjing 147
Dong Ket 142
Boston 139
Jacksonville 123
New York 116
Tokyo 110
Council Bluffs 104
Des Moines 99
Buffalo 97
Wilmington 94
Da Nang 88
Munich 88
São Paulo 88
Amsterdam 85
Rome 82
Milan 80
Redondo Beach 80
Haiphong 66
Orem 65
Dublin 64
Ottawa 60
Lawrence 56
Frankfurt am Main 54
Warsaw 52
Dallas 49
Montreal 47
Bucharest 46
Mexico City 45
Seattle 43
Helsinki 41
Nanchang 41
Denver 39
Caserta 37
Brooklyn 36
Houston 36
Nuremberg 36
Seoul 35
Johannesburg 34
Chennai 33
Hải Dương 33
Chicago 32
Toronto 32
Poplar 31
Rio de Janeiro 31
Shenyang 31
Stockholm 31
Baghdad 28
Buenos Aires 28
Hebei 28
Tianjin 28
London 27
Phoenix 26
Turku 26
Atlanta 25
San Francisco 25
Biên Hòa 24
Boardman 24
Washington 22
Falkenstein 21
Can Tho 20
Redwood City 20
Woodbridge 20
Norwalk 19
Augusta 17
Brasília 17
Jiaxing 17
Ninh Bình 17
Manchester 16
Nairobi 16
Shanghai 16
Florence 15
New Delhi 15
Querétaro 15
Quito 15
Tashkent 15
Bangkok 14
Changsha 14
Turin 14
Vienna 14
Amman 13
Belo Horizonte 13
Mumbai 13
Totale 12.431
Salva come PNG Salva come JPEG
Nome #
Polimirfismo del gene dell'ACE ed eritrocitosi nel trapianto di rene 459
Il nefrologo nel trattamento dell’iperammoniemia da disordini del ciclo dell’urea 423
Experimental evidence and clinical implications of Warburg effect in the skeletal muscle of Fabry disease 189
Endocrine dysfunction in patients with Fabry disease 188
Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases 188
Effect of a Short-Course Treatment with Synbiotics on Plasma p-Cresol Concentration in Kidney Transplant Recipients. 185
Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis 184
Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease 182
Alterations of functional connectivity of the motor cortex in Fabry disease: An RS-fMRI study 171
Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer 165
EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. 161
Pituitary function and morphology in Fabry disease. 158
Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial 156
6-tips diet: a simplified dietary approach in patients with chronic renal disease. A clinical randomized trial 152
Cardiopulmonary determinants of reduced exercise tolerance in Fabry disease 152
Striatonigral involvement in Fabry Disease: A quantitative and volumetric Magnetic Resonance Imaging study 150
Parapelvic cysts, a distinguishing feature of renal Fabry Disease. 149
Current tissue molecular markers in colorectal cancer: A literature review 148
Hybrid positron emission tomography-magnetic resonance imaging for assessing different stages of cardiac impairment in patients with Anderson-Fabry disease: AFFINITY study group 147
RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study 146
Immunosuppression and multiple primary malignancies in kidney transplanted patients. A single-institute study 146
Cerebrovascular and Brain Abnormalities In Autosomal-Dominant Polycystic Kidney Disease: Role Of 3d Time-of-Flight Magnetic Resonance Angiography 146
Nutritional management in renal transplant recipients: A transplant team opportunity to improve graft survival 146
Atorvastatin improves the course of ischemic acute renal failure in aging rats 145
Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial 145
Renal sympathetic-nerve ablation for uncontrolled hypertension in a patient with single-kidney autosomal dominant polycystic kidney disease. 144
Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis 144
The central vein sign helps in differentiating multiple sclerosis from its mimickers: lessons from Fabry disease 143
Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by (123)I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease 143
Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review 142
Real-world management of chronic and postprandial hyperkalemia in CKD patients treated with patiromer: a single-center retrospective study 141
A strange epigastric pain. 141
The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials 141
Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: A randomized trial 140
Default mode network modifications in Fabry disease: A resting-state fMRI study with structural correlations 140
Reduced intracranial volume in Fabry Disease: Evidence of abnormal neurodevelopment? 140
Identifying Fabry patients in dialysis population: prevalence of GLA mutations by renal clinic screening, 1995–2019 140
Molecular Mechanisms of Renal Cellular Nephrotoxicity due to Radiocontrast Media 139
C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial 138
Early Biomarkers of Fabry Nephropathy: A Review of the Literature. 136
Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease. 135
Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease 135
Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis. 135
A novel GLA mutation in a Fabry family with glucose-6-phosphate dehydrogenase deficiency 133
Endothelial-mediated coronary flow reserve in patients with Anderson-Fabry disease 133
Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: A cross-sectional study 131
Advanced CMR Techniques in Anderson-Fabry Disease: State of the Art 130
Familial polycystic kidneys with no genetic confirmation: Are we sure it is ADPKD? 129
Genetic variants associated with gastrointestinal symptoms in Fabry disease. 129
Neuroimaging in Fabry disease: current knowledge and future directions 129
Fatigue as hallmark of Fabry disease: role of bioenergetic alterations 128
Thyroid function in Fabry disease before and after enzyme replacement therapy. 128
Prominent longitudinal strain reduction of left ventricular basal segments in treatment-naïve Anderson-Fabry disease patients 128
Optical Coherence Tomography Angiography Findings in Fabry Disease 128
Arginase inhibition slows the progression of renal failure in rats with renal ablation 127
ADPKD and metformin: from bench to bedside 127
Ketogenic diet in ADPKD patient 127
Increased Expression of Orexin-A in Patients Affected by Polycystic Kidney Disease 125
Parapelvic Cysts: An Imaging Marker of Kidney Disease Potentially Leading to the Diagnosis of Treatable Rare Genetic Disorders? A Narrative Review of the Literature 125
Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. 125
Cardiac performance during exercise in patients with Fabry's disease 125
Motor involvement in Fabry disease 125
An unusual case of tuberous sclerosis incidentally discovered in adulthood: case report and review of the literature 124
Insomnia in maintenance haemodialysis patients. 121
Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy. 121
Early Cardiac Involvement Affects Left Ventricular Longitudinal Function in Females Carrying α-Galactosidase A Mutation: Role of Hybrid Positron Emission Tomography and Magnetic Resonance Imaging and Speckle-Tracking Echocardiography 121
Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol 120
Methylome Profiling in Fabry Disease in Clinical Practice: A Proof of Concept 120
Metabolic effects of two low protein diets in chronic kidney disease stage 4-5--a randomized controlled trial. 119
Prevention of contrast-induced nephropathy through a knowledge of its pathogenesis and risk factors 119
Randomized Controlled Trials on Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease Stages 3-5: Are They Robust? A Fragility Index Analysis 118
The Choice of the Iodinated Radiographic Contrast Media to Prevent Contrast-Induced Nephropathy 118
Home infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative group 118
Therapeutic advances in ADPKD: the future awaits 118
Molecular and clinical studies in five index cases with novel mutations in the GLA gene. 117
Visceral Leishmaniasis in renal transplant recipients. Is it still a challange to the Nephrologist? 116
Atrial septum aneurysm: an unusual manifestation in ADPKD? 116
Layer-specific longitudinal strain in Anderson–Fabry disease at diagnosis: A speckle tracking echocardiography analysis 116
Assessing brain involvement in Fabry disease with deep learning and the brain‐age paradigm 115
Terapia enzimatica sostitutiva nella malattia di Fabry: cosa abbiamo imparato dallo switch? 115
Redefining the Pulvinar Sign in Fabry Disease 115
Author response: Alterations of functional connectivity of the motor cortex in Fabry disease: An RS-fMRI study 115
Ultra-deep dna methylation analysis of x-linked genes: Gla and ar as model genes [*De Riso G., Cuomo M co-primi autori] 115
Effects of atorvastatin on renal function in patients with chronic renal failure. 114
Fabry's disease: a comparison of the effectiveness of two different enzyme replacement therapies 114
Mutations in the GLA gene and LysoGb3: Is it really Anderson-Fabry disease? 114
Cardiovascular magnetic resonance native T1 mapping in Anderson-Fabry disease: a systematic review and meta-analysis 114
Antiproteinuric effect of add-on paricalcitol in Fabry disease patients: a prospective observational study. 113
Effect of a low- versus moderate-protein diet on progression of CKD: follow-up of a randomized controlled trial. 113
Multimodality imaging approach to Fabry cardiomyopathy: Any role for nuclear cardiology? 113
Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial 113
The role of immunosuppressive therapy in aneurysmal degeneration of hemodialysis fistulas in renal transplant patients: Aneurysmatic arteriovenous fistula in transplant patients 113
Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature 112
Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter? 111
Visceral Leishmaniasis in renal transplant recipients: is it still a challenge to the nephrologist? 110
Renal denervation in ADPKD: an exceptional case 110
Role of serial cardiac 18F-FDG PET-MRI in Anderson-Fabry disease: a pilot study 110
Clinical and Pathophysiologic Correlates of Basilar Artery Measurements in Fabry Disease 109
Microstructural damage of the cortico-striatal and thalamo-cortical fibers in Fabry disease: a diffusion MRI tractometry study 108
Effects of Ha-Ras inhibition on ischemic acute renal failure in the rat 108
Totale 13.906
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.108
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.108
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021166 0 0 0 0 0 0 0 0 0 0 0 166
2021/20221.182 20 4 11 13 15 37 37 52 112 109 261 511
2022/20231.347 222 125 50 119 144 147 19 126 221 79 73 22
2023/20241.190 56 276 107 62 69 112 24 102 27 25 247 83
2024/20256.013 339 317 38 110 124 369 631 345 505 626 2.082 527
2025/202612.472 1.399 920 1.195 1.233 2.218 523 1.370 781 1.278 915 548 92
Totale 24.624